Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim ... - Morningstar
Savara presents Phase 3 IMPALA-2 trial data at ERS 2024 showing significant improvements in disease severity, DLCO%, SGRQ Total Score, and GGO with molgramostim in aPAP patients.
Highlighted Terms
Related News
Savara presents Phase 3 IMPALA-2 trial data at ERS 2024 showing significant improvements in disease severity, DLCO%, SGRQ Total Score, and GGO with molgramostim in aPAP patients.
New data from the IMPALA-2 trial shows molgramostim significantly improves disease severity, DLCO%, SGRQ Total Score, and GGO in aPAP patients compared to placebo at Weeks 24 and 48.
Savara Inc. presented Phase 3 IMPALA-2 trial data of molgramostim for aPAP at ERS Congress 2024, showing significant DLCO% improvement at Week 24, sustained through Week 48, with additional improvements in Disease Severity Score, DLCO% responders, SGRQ Total Score, and Ground Glass Opacification Score. Molgramostim was well-tolerated, and Savara plans to complete the BLA submission in H1 2025.
Molgramostim showed significant improvement in disease severity score (DSS), DLCO% responder analysis, SGRQ Total Score, and GGO score compared to placebo at Weeks 24 and 48 in aPAP patients, according to IMPALA-2 trial data presented at ERS 2024.
Molgramostim showed significant improvements in Disease Severity Score (DSS), DLCO% responders, St. George's Respiratory Questionnaire (SGRQ) Total Score, and Ground Glass Opacification (GGO) compared to placebo at Weeks 24 and 48 in aPAP patients.